News | Proton Therapy | September 21, 2015

Facility to begin treating patients at the end of 2018

September 21, 2015 — IBA (Ion Beam Applications SA) announced that it has signed a contract with the company INVAP for the installation of a proton therapy center at the Instituto de Oncologia Angel Roffo hospital in Buenos Aires, Argentina.

IBA will equip the new center with its ProteusPlus system, including one gantry treatment room with next-generation pencil beam scanning capability and one research and development room. The contract will also include an operation and maintenance agreement. The equipment and services that will be supplied by IBA are worth between EUR 35 and 40 million to IBA.

This first proton therapy center to be installed in Latin America is part of the implementation of the Nuclear Medicine National Plan of the Argentine Ministry of Federal Planning, Public Investment and Services, together with the Ministry of Health and the National Atomic Energy Commission (CNEA). The Nuclear Medicine National Plan is a unique government plan of investment in infrastructure and equipment designed to ensure free access to the highest standards in prevention, treatment, research and training in nuclear medicine and oncology. It is expected that the center will treat its first patient at the end of 2018.

The Argentine Minister of Federal Planning, Public Investment and Services, Julio De Vido, commented: "Bringing an innovative new cancer center closer to the people has the objective to give better chances to fight this severe disease. Argentina is the first country in Latin America to have access to this unique medical technology which will be beneficial for the health of patients in the country.”

For more information: www.iba-worldwide.com

Related Content

News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
News | Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

Time July 27, 2022
arrow
News | Radiation Oncology

July 25, 2022 — RaySearch Laboratories AB announces the launch of RayStation* 12A, the latest version of the company’s ...

Time July 25, 2022
arrow
News | PET Imaging

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
arrow
News | Radiopharmaceuticals and Tracers

July 20, 2022 — -NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 20, 2022
arrow
Subscribe Now